Welcome to our dedicated page for Anika Therapeutics SEC filings (Ticker: ANIK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Anika Therapeutics, Inc. (NASDAQ: ANIK) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Anika uses these filings to report its financial results, clinical and regulatory milestones, governance decisions, and equity compensation arrangements as it advances osteoarthritis pain management and regenerative orthopedic solutions based on hyaluronic acid and implant technologies.
Investors can review Form 8-K current reports in which Anika furnishes press releases on quarterly financial results, such as those for the second and third quarters of 2025, and discusses non-GAAP measures like Adjusted EBITDA and adjusted net income from continuing operations. Other 8-K filings describe material events including the filing of the third and final Premarket Approval (PMA) module for the Hyalofast cartilage repair scaffold, topline results from the U.S. pivotal FastTRACK Phase III study, and amendments to the company’s 2017 Omnibus Incentive Plan approved by stockholders.
Through its proxy-related disclosures and meeting results, Anika reports on governance and compensation matters, including director elections, advisory votes on executive compensation, and increases to share reserves under its omnibus incentive plan. Additional filings document inducement equity grants made under a separate inducement plan in accordance with Nasdaq Listing Rule 5635(c)(4), providing detail on stock option terms and vesting conditions for newly hired employees.
On Stock Titan, these filings are complemented by AI-powered summaries that highlight key points from lengthy documents, helping users quickly understand the implications of earnings releases, clinical and regulatory updates, plan amendments, and other material events. Users can track new 8-Ks and other SEC forms as they are posted to EDGAR, and use the summaries to focus on the sections most relevant to Anika’s OA pain management and regenerative solutions strategy, capital structure, and corporate governance.
Anika Therapeutics SVP, CAO & Treasurer Ian McLeod received new equity awards. On March 19, 2026, he was granted 13,097 Restricted Stock Units and a separate 11,194 RSU award, each representing a contingent right to one share of common stock or cash on vesting. He also received 17,663 Premium Priced Stock Appreciation Rights with a $15.60 exercise price, vesting in three annual installments starting March 19, 2027, and expiring on March 19, 2036.
Anika Therapeutics EVP and General Counsel David Colleran reported equity award vesting and related tax withholding, not open-market trading. On March 14, 2026 and March 15, 2026, he exercised a total of 15,837 restricted stock units into the same number of common shares at $0.00 per share.
He also received a grant or award of 4,694 common shares. To cover tax obligations on these RSU and PSU vestings, 4,168 and 1,893 shares of common stock were withheld at $14.20 per share. Following these transactions, Colleran directly holds 67,570 shares of Anika Therapeutics common stock, with additional RSU awards continuing to vest over time as indicated in the footnotes.
Anika Therapeutics President and CEO Stephen D. Griffin reported equity compensation activity tied to vesting restricted stock units. On March 14, 2026, he exercised 12,824 restricted stock units, receiving 12,824 shares of common stock at a stated exercise price of $0.00 per share.
On the same date, he also acquired 6,412 shares of common stock as a grant or award, and 5,944 shares were withheld by the company at $14.20 per share to cover tax obligations related to vested RSUs and PSUs. Following these transactions, Griffin directly owns 23,963 shares of Anika Therapeutics common stock.
Anika Therapeutics director Cheryl R. Blanchard reported compensation-related stock activity involving restricted stock units (RSUs) and performance-based RSUs (PSUs). On March 14, 2026, 24,519 RSUs and 24,519 PSUs vested and were converted into common shares, and she also received a grant of 24,520 common shares.
On March 15, 2026, an additional 25,131 RSUs vested and were converted into 25,131 common shares. To cover related tax withholding obligations, the company retained 14,728 shares on March 14 and 12,104 shares on March 15 at a price of $14.20 per share, rather than selling shares in the open market.
Following these transactions, Blanchard directly holds 258,788 common shares and indirectly holds 11,742 shares through a revocable trust of which she is the sole trustee and a beneficiary. The transactions reflect equity awards vesting and associated tax withholding, not open-market purchases or sales.
Anika Therapeutics SVP, CAO & Treasurer Ian McLeod reported compensation-related stock activity, mainly from vesting of prior equity awards. On March 14, 2026, he exercised restricted stock units for 3,774 shares of common stock and received an additional 1,161 shares as a grant or award. On March 15, 2026, he exercised further restricted stock units for 2,658 shares. To cover tax withholding obligations tied to these RSU and PSU vestings, the issuer retained 1,449 shares on March 14 and 781 shares on March 15 at $14.20 per share, which are coded as tax-withholding dispositions rather than open-market sales. Following these transactions, McLeod directly holds 24,107 shares of Anika common stock and 2,659 restricted stock units.
Anika Therapeutics EVP and General Counsel David Colleran reported routine equity compensation activity tied to previously granted restricted stock units (RSUs). On March 9, 2026, 5,465 RSUs from a March 9, 2023 grant vested and were converted into an equal number of common shares at no exercise price.
To cover tax withholding on the vesting, 1,919 common shares were retained by the company at a price of $14.96 per share, as a tax-withholding disposition rather than a market sale. After these transactions, Colleran directly holds 53,100 shares of Anika Therapeutics common stock.
Anika Therapeutics director Cheryl R. Blanchard reported the vesting of 20,001 restricted stock units into common shares. Each RSU converts into one share of common stock, and this represents the third and final installment of a 60,004-unit award granted on March 9, 2023.
Of the vested shares, 5,871 were withheld by the company at $14.96 per share to cover tax obligations, leaving a net increase of 14,130 shares. Following these transactions, Blanchard holds 211,450 shares directly and an additional 11,742 shares indirectly through a revocable trust of which she is the sole trustee and a beneficiary.
Anika Therapeutics, Inc. SVP, CAO & Treasurer Ian McLeod completed the final vesting of a prior RSU grant and related tax withholding. On March 9, 2026, 2,197 restricted stock units converted into 2,197 shares of common stock, representing the third and final installment of a 6,590‑RSU award granted on March 9, 2023. To cover tax obligations on this vesting, 639 shares were retained by the company at a price of $14.96 per share, leaving a net 1,558 shares from this tranche. After these transactions, McLeod directly holds 18,744 shares of Anika Therapeutics common stock.
Anika Therapeutics outlines a major strategic shift toward osteoarthritis (OA) pain management and regenerative orthopedic solutions built on its hyaluronic acid (HA) technology. The company has exited earlier acquisitions by selling Arthrosurface for a ten‑year, non‑interest‑bearing $7.0 million promissory note plus potential contingent payments, and Parcus Medical for $4.5 million in cash, sharpening focus on higher‑priority HA programs.
Growth is centered on OA products Monovisc and Orthovisc, marketed in the U.S. through a long‑standing exclusive partnership with J&J MedTech, which accounted for 50% of 2025 revenue, and on the Integrity Implant System for tendon augmentation, which is gaining surgical adoption. Anika is advancing Cingal toward a U.S. NDA with ongoing bioequivalence work and pursuing FDA approval of Hyalofast after submitting a PMA, though the FDA has issued a deficiency letter the company is working to address. Research and development spending rose to $25.8 million in 2025 to support these regulatory and clinical programs, while the 10‑K also highlights competitive pressures, manufacturing and supply‑chain concentration, heavy customer reliance, and extensive global regulatory, reimbursement, cybersecurity, data‑privacy, and product‑liability risks.
Anika Therapeutics reported fourth quarter and full-year 2025 results and outlined leadership transition plans for its General Counsel. Q4 2025 revenue was $30.6 million, essentially flat year over year, with gross margin expanding to 63%. Commercial Channel revenue grew 22% while OEM Channel revenue declined 12%.
For full-year 2025, revenue was $112.8 million, down 6% from 2024, but gross margin improved to 57%. The company generated $11.2 million in operating cash flow and $4.4 million in free cash flow, and reduced its net loss to $10.9 million from $56.4 million in 2024. Adjusted EBITDA was $5.3 million in 2025 versus $15.5 million in 2024.
Anika continued a $15 million Rule 10b5-1 share repurchase program, funding $10.7 million to date and expecting completion in the second quarter of 2026. The company received an FDA response to its Hyalofast PMA in January 2026 and is preparing follow-up submissions, while progressing remaining requirements for the Cingal NDA. Separately, Anika entered a Transition Agreement under which Executive Vice President, General Counsel and Corporate Secretary David Colleran will remain in his role through May 1, 2026, with continued salary, benefits, and equity vesting, and will receive separation benefits pursuant to his Executive Retention Agreement in exchange for a general release of claims.